

CORRECTION

Open Access



Correction: Characteristics and outcomes of patients with *RET*-fusion positive non-small lung cancer in real-world practice in the United States

Lisa M. Hess^{1*} , Yimei Han¹, Yajun Emily Zhu¹, Naleen Raj Bhandari¹ and Anthony Sireci²

Correction: *BMC Cancer* 21, 28 (2021)

<https://doi.org/10.1186/s12885-020-07714-3>

Following publication of the original article [1], the authors identified an error in the caption of table 4.

In the published article [1], the title of Table 4 is “Progression-free and overall survival of RET+ versus RET- cohorts from start of first-line therapy,” which should be corrected to read “Progression-free and overall survival of **RET-** versus **RET+** cohorts from start of first-line therapy,” (correction in bold) to correctly indicate the direction of the hazard ratios.

References

1. Hess LM, Han Y, Zhu YE, et al. Characteristics and outcomes of patients with *RET*-fusion positive non-small lung cancer in real-world practice in the United States. *BMC Cancer*. 2021;21:28. <https://doi.org/10.1186/s12885-020-07714-3>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Published online: 26 April 2023

The online version of the original article can be found at <https://doi.org/10.1186/s12885-020-07714-3>

*Correspondence:

Lisa M. Hess
Hess_lisa_m@lilly.com

¹Eli Lilly and Company, Indianapolis IN 46254, USA

²Loxo Oncology at Lilly, a wholly owned subsidiary of Eli Lilly and Company, Stamford, CT, USA



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.